Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 287

1.

A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Setric J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP.

PLoS One. 2016 Sep 16;11(9):e0162866. doi: 10.1371/journal.pone.0162866. eCollection 2016.

2.

Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.

Wakamiya T, Hokosaki T, Tsujimoto S, Kadota K, Nakano Y, Watanabe S, Iwamoto M, Yanagimachi M, Ito S.

Mol Diagn Ther. 2016 Aug;20(4):393-400. doi: 10.1007/s40291-016-0212-5. Erratum in: Mol Diagn Ther. 2016 Oct;20(5):501.

PMID:
27262824
3.

Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients.

Cho SM, Lee KY, Choi JR, Lee KA.

Yonsei Med J. 2016 May;57(3):635-40. doi: 10.3349/ymj.2016.57.3.635.

4.

Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals.

Alrashid MH, Al-Serri A, Alshemmari SH, Koshi P, Al-Bustan SA.

Mol Diagn Ther. 2016 Apr;20(2):183-90. doi: 10.1007/s40291-016-0190-7.

PMID:
26940072
5.

[FREQUENCY OF POLYMORPHISM OF VKORC1 AND CYP2C9 GENES IN TWO REGIONS OF GEORGIA].

Jokhadze T, Kakauridze N, Buadze T, Gaiozishvili M, Lezhava T.

Georgian Med News. 2016 Jan;(250):46-51. Russian.

PMID:
26870974
6.

[Effect of VKORC1 and CYP2C9 variants on dosage of oral anticoagulants in Chilean individuals].

Benavides F, Grossman N, Poggi H, Nieto E, Bertrán A, Araos D, Vásquez M, Ibarra I, Cáceres F, Espinoza K, Lagos M, Repetto M G.

Rev Med Chil. 2015 Nov;143(11):1369-76. doi: 10.4067/S0034-98872015001100001. Spanish. Erratum in: Rev Med Chil. 2016 Jan;144(1):136-7. Lagos, Marcel [corrected to Lagos, Marcela].

7.

[Comparison of Empiric and Pharmacogenetic Approaches in Assessment of Efficacy of Anticoagulant Therapy].

Kokh NV, Slepukhina AA, Tsvetovskaya GA, Lifshits GA.

Kardiologiia. 2015;55(4):57-60. Russian.

PMID:
26502504
8.

CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement.

Wypasek E, Cieśla M, Suder B, Janik Ł, Sadowski J, Undas A.

Adv Clin Exp Med. 2015 Jul-Aug;24(4):607-14. doi: 10.17219/acem/32577.

9.
10.

Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient.

Dai DP, Li CB, Wang SH, Cai J, Geng PW, Zhou YF, Hu GX, Cai JP.

Pharmacogenomics. 2015;16(13):1475-86. doi: 10.2217/pgs.15.89. Epub 2015 Aug 10.

PMID:
26255664
11.

The Influence of VKORC1 Polymorphisms on Warfarin Doses in Thai Patients with Deep Vein Thrombosis.

Sermsathanasawadi N, Sritongsathian C, Pongrattanaman N, Praditsuktavorn B, Hongku K, Wongwanit C, Ruangsetakit C, Chinsakchai K, Mutirangura P, Poungvarin N.

J Med Assoc Thai. 2015 Jun;98(6):549-54.

PMID:
26219158
12.

Could MicroRNA polymorphisms influence warfarin dosing? A pharmacogenetics study on mir133 genes.

Ciccacci C, Rufini S, Politi C, Novelli G, Forte V, Borgiani P.

Thromb Res. 2015 Aug;136(2):367-70. doi: 10.1016/j.thromres.2015.06.026. Epub 2015 Jun 18.

PMID:
26113018
13.

National Coverage Determination (NCD) for Pharmacogenomic Testing for Warfarin Response (90.1).

Medicare National Coverage Determinations [Internet]. Baltimore (MD): Centers for Medicare & Medicaid Services (US); 2009-.

14.

Identification and Functional Assessment of a New CYP2C9 Allelic Variant CYP2C9*59.

Dai DP, Wang SH, Li CB, Geng PW, Cai J, Wang H, Hu GX, Cai JP.

Drug Metab Dispos. 2015 Aug;43(8):1246-9. doi: 10.1124/dmd.115.063412. Epub 2015 May 20.

15.

Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR.

Yasmeen F, Ghafoor MB, Khalid AW, Latif W, Mohsin S, Khaliq S.

J Thromb Thrombolysis. 2015 Aug;40(2):218-24. doi: 10.1007/s11239-015-1215-5.

PMID:
25904339
16.

Long-term risk of pulmonary embolism in solid-organ transplant recipients.

Küpeli E, Ulubay G, Doğrul I, Birben Ö, Seyfettin P, Özsancak Uğurlu A, Öner Eyüboğlu F, Haberal M.

Exp Clin Transplant. 2015 Apr;13 Suppl 1:223-7.

PMID:
25894159
17.

GAS6 intron 8 c.834 + 7G > A gene polymorphism in diabetic nephropathy.

Erkoc R, Cikrikcioglu MA, Aintab E, Toprak AE, Kilic U, Gok O, Cetin AI, Zorlu M, Kiskac M, Cakirca M, Erkal SN, Isen HC, Karatoprak C.

Ren Fail. 2015 Jun;37(5):866-70. doi: 10.3109/0886022X.2015.1034606. Epub 2015 Apr 14.

PMID:
25869052
18.

Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy.

Hirai K, Yamada Y, Hayashi H, Tanaka M, Izumiya K, Suzuki M, Yoshizawa M, Moriwaki H, Akimoto T, Tsuji D, Inoue K, Itoh K.

Thromb Res. 2015 May;135(5):861-6. doi: 10.1016/j.thromres.2015.02.019. Epub 2015 Feb 27.

PMID:
25747538
19.

CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy.

Chang M, Söderberg MM, Scordo MG, Tybring G, Dahl ML.

Eur J Clin Pharmacol. 2015 Apr;71(4):433-9. doi: 10.1007/s00228-015-1812-4. Epub 2015 Feb 6.

PMID:
25652102
20.

Genotype-guided coumarin dosing: where are we now and where do we need to go next?

Baranova EV, Verhoef TI, Asselbergs FW, de Boer A, Maitland-van der Zee AH.

Expert Opin Drug Metab Toxicol. 2015 Apr;11(4):509-22. doi: 10.1517/17425255.2015.1004053. Epub 2015 Jan 16. Review.

PMID:
25595525
Items per page

Supplemental Content

Loading ...
Write to the Help Desk